Sponsor:
Becton, Dickinson and Company
Code:
NCT07148323
Conditions
Hemodynamic Instability
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
HemoSphere Alta Monitor, Swan-Ganz IQ pulmonary arterial catheter, ForeSight IQ Large sensor, and Acumen IQ sensor
Brief summary:
Conditions
Hemodynamic Instability
Study ID
NCT07148323
Start date
Oct 14, 2025
Status verified date
Aug, 2026
Completion date
Dec, 2026
Anticipated
Primary completion date
Nov, 2026
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
100 participants
Anticipated
Arms
Primary Cohort (Swan)
Interventions
HemoSphere Alta Monitor, Swan-Ganz IQ pulmonary arterial catheter, ForeSight IQ Large sensor, and Acumen IQ sensor
Primary outcome measure
Central contacts
Locations
University of Rochester Medical Center
Recruiting
Rochester, New York, United States, 14620
Sponsor
Becton, Dickinson and Company
Last update posted
Aug 26, 2026
Last verified
Aug, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Becton, Dickinson and Company on 2026-08-26.